ReviewNature reviews. Drug discovery2026
Contemporary design of small-molecule kinase modulators: orthosteric, allosteric and induced-proximity strategies.
Review in Nature reviews. Drug discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Substrate-Derived Peptides for Selective Covalent Inhibition of Protein Tyrosine Kinases.ACS chemical biology · 2026Article
- Substrate-derived peptides for selective covalent inhibition of protein tyrosine kinases.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Small-molecule kinase modulators are an expanding class of compounds with broad impact on biology and medicine. However, although currently 100 inhibitors are FDA approved, many disease-linked kinases remain intractable to conventional therapeutic approaches. Key challenges include selectivity, modulation of scaffolding functions and overcoming drug resistance. Here, we review the expanding toolkit for kinase modulation, comparing traditional ATP-site inhibitors with emerging classes of allosteric modulators and proximity-inducing molecules such as molecular glues and heterobivalent degraders. Through representative case studies, we illustrate how these novel chemical approaches can overcome the limitations of traditional inhibitors and discuss future innovations poised to deliver the next generation of kinase-targeted therapies.
Indexed as
Identifiers
42049946What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.